Phage Therapy for Staph Infection

(PHAGE-2024-01 Trial)

SD
BW
Overseen ByBenson Weyant, MD
Age: Any Age
Sex: Male
Trial Phase: Phase 1 & 2
Sponsor: University of Calgary
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial tests a new treatment called phage therapy, which uses viruses to target bacteria, to address stubborn hip joint infections caused by Staphylococcus aureus. The goal is to determine if this approach can clear the infection and prevent its recurrence, particularly for those who haven't succeeded with other treatments. Participants should have a long-term hip joint infection that hasn't improved despite multiple antibiotics and surgeries. As a Phase 1 trial, this research aims to understand how the treatment works in people, offering participants the opportunity to be among the first to receive this innovative therapy.

Will I have to stop taking my current medications?

The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.

Is there any evidence suggesting that phage therapy is likely to be safe for humans?

Research has shown that phage therapy is generally safe for treating severe Staphylococcus aureus infections. Studies have found that a specific mix of bacteriophages, called AB-SA01, is well-tolerated, even in serious conditions like heart infections and septic shock, meaning the treatment usually doesn't cause harmful side effects.

Further research supports that phage therapy can effectively reduce infections and help wounds heal faster in infected areas. Animal tests have studied both injecting phages into the vein and applying them directly to the infection for safety and effectiveness.

The trial for phage therapy involves administering it directly into the joint and through the veins. This method is being tested because earlier research showed positive results in treating stubborn Staphylococcus infections. Although the trial is still in its early stages, existing data on phage therapy's safety is promising for potential participants.12345

Why do researchers think this study treatment might be promising?

Phage therapy is unique because it uses bacteriophages, which are viruses that specifically target and destroy bacteria, to treat infections like those caused by Staphylococcus. Unlike antibiotics, which can sometimes lead to resistance and affect beneficial bacteria, phages are highly specific, targeting only the harmful bacteria. Researchers are excited about this treatment because it offers a promising alternative that could potentially overcome antibiotic resistance and provide a targeted, efficient way to eliminate stubborn bacterial infections.

What evidence suggests that phage therapy might be an effective treatment for Staph infection?

Research has shown that phage therapy, which uses viruses to attack bacteria, could help treat Staphylococcus aureus infections. One study found that using phage therapy soon after infection prevented abscesses from forming. Another review noted that phage therapy might work well alongside other treatments for Staphylococcus infections, even in challenging cases involving biofilms. Clinical data indicates that about 77% of infections improved with phage therapy, and 61% of the bacteria were completely eliminated. These findings suggest that phage therapy, which participants in this trial will receive, could be an effective option for treating stubborn infections.34567

Are You a Good Fit for This Trial?

This trial is for someone with a chronic hip joint infection caused by methicillin-sensitive Staphylococcus aureus, who has tried multiple antibiotics and surgeries without success. The bacteria causing their infection must respond to bacteriophage therapy in lab tests.

Inclusion Criteria

I have an ongoing infection in my artificial joint.
The bacteria causing my infection can be treated with bacteriophage therapy.
I've had several unsuccessful antibiotic treatments and surgeries.

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

1-2 weeks

Treatment

Administration of bacteriophage therapy, including intra-operative injection and 14 days of intravenous phage therapy

2 weeks
Daily visits for intravenous therapy

Follow-up

Participants are monitored for safety and effectiveness after treatment, including regular physical examinations and blood tests

12 months
Monthly assessments

What Are the Treatments Tested in This Trial?

Interventions

  • Phage therapy
Trial Overview The study is testing a one-time injection of a bacteriophage cocktail directly into the infected hip joint during surgery, followed by two weeks of intravenous phage therapy. It aims to clear the infection and prevent it from coming back.
How Is the Trial Designed?
1Treatment groups
Experimental Treatment
Group I: Open Label ArmExperimental Treatment1 Intervention

Find a Clinic Near You

Who Is Running the Clinical Trial?

University of Calgary

Lead Sponsor

Trials
827
Recruited
902,000+

Precisio Biotix Therapeutics, Inc.

Industry Sponsor

Trials
3
Recruited
80+

University of Toronto

Collaborator

Trials
739
Recruited
1,125,000+

Citations

Bacteriophage Therapy for Staphylococcus Aureus InfectionsFour to six days after infection, the phage treatment showed to be effective in preventing abscess development when the phages were administered simultaneously ...
Phage therapy: a promising approach for Staphylococcus ...This review evaluates the efficacy of phage therapy as a complementary treatment for DFIs caused by S. aureus, synthesizing evidence from preclinical and ...
Efficacy of phage therapy in controlling staphylococcal biofilmsResults showed that both pre-phage and post-antibiotic treatments were effective, with survival rates varying based on biofilm strength. The ...
Personalized bacteriophage therapy outcomes for 100 ...Clinical improvement was reported in 77.2% (88/114) of targeted infections and eradication of the targeted bacteria was observed in 61.3% (65/ ...
intravenous versus local application in sheepRecent case reports and small-scale clinical studies have shown encouraging results for phage therapy (PT), including for antibiotic-resistant infections and ...
6.pubmed.ncbi.nlm.nih.govpubmed.ncbi.nlm.nih.gov/32066959/
Safety of bacteriophage therapy in severe Staphylococcus ...Our data indicate that AB-SA01 administered in this way is safe in severe S. aureus infections, including infective endocarditis and septic shock.
Safety of bacteriophage therapy in severe Staphylococcus ...Our data indicate that AB-SA01 administered in this way is safe in severe S. aureus infections, including infective endocarditis and septic shock.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security